Mineralys Therapeutics reports inducement awards under Nasdaq Rule
Mineralys Therapeutics, Inc. said it has issued inducement awards under Nasdaq Listing Rule 5635(c)(4).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results.
MLYS - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
MLYS - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics reports inducement awards under Nasdaq Rule 5635(c)(4)
RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. NASDAQ:MLYS, a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and ot…
MLYS - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
MLYS - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)